De Novo Pharmaceuticals

A more rational approach to drug design

De Novo is a world leader in in-silico, de novo drug design.De Novo’s technology offers the following advantages to drug developers:-

• lower cost – in-silico design reduces wasted effort in synthesis and HTS
• rapid – typically less than 6 months target to hits
• lower molecular weight hits – allows greater scope for medicinal chemists to optimise molecules
• novel – explore trillions of drug like molecules
• patentable hit molecules – composition of matter claims free from existing IP

De Novo’s technology is derived from a substantial body of research over thirty years in the Department of Pharmacology at the University of Cambridge and is used by Roche in their in-house drug discovery process.